Table 2.

Broader coverage of antibody responses to SARS-CoV-2 antigens in individual patients using MSD multiplex platform.^a

Patient ID	Days post-PCR	Abbott (≥1.4 S/Co b )	EUROIMMUN (≥1.1 S/Co)	Siemens (≥1.0 S/Co)	MSD S (>869 AU/mL)	MSD N (>7225 AU/mL)	MSD RBD (>592 AU/mL)
7–14 days post-PCR
632	7	POSc	NEGd	NEG	POS	POS	POS
336	8	NEG	NEG	NEG	POS	POS	NEG
322	10	POS	NEG	POS	POS	POS	POS
619	11	POS	NEG	NEG	POS	POS	NEG
929	14	POS	NEG	NTe	POS	POS	POS
>14 days post-PCR
941	19	POS	NEG	POS	POS	POS	NEG
945	22	NEG	INDf	POS	POS	NEG	POS
622	26	POS	IND	POS	POS	POS	POS
929	30	NEG	POS	POS	POS	NEG	POS

^aPatients with negative results from each commercial IgG assays were compared qualitatively to antibodies detected on MSD platform individually and combined.

^bSignal/calibrator.

^cPositive.

^dNegative.

^eNot tested.

^fIndeterminate.